Search Menu Globe Arrow Right Close

Lab Reagents and Resources

Prediman Krishan Shah, MD, and Behrooz Sharifi, PhD, resources for current animal models developed for atherosclerosis research:

  • Mouse Model for Myocardial Infarction
  • Aortic Construction: A Technique to Produce Left Ventricular Hypertrophy in Mice
  • Mouse Cervical Cardiac Transplantation
  • Artery Injury Model for Atherosclerosis
  • Directed Vascular Graft Regeneration in Mice Peritoneal Cavity
  • Peritoneal Cavity Bone Marrow Transplantation for Gene Therapy and Atherosclerosis

Shah and Sharifi resources for knock-out mouse models:

  • Tenascin-C (TNC) KO
  • Pleiotrophin (PTN) KO
  • GATA3 Gene Conditional (GATA3) KO
  • Krüppel-like Factor 14 (KLF14) KO
  • Apolipoprotein E / Apolipoprotein A1 (ApoE/ApoA1) KO
  • Delta DBL GATA KO (Eosinophils KO)
  • Eotaxin 1,2 KO
  • C57 BL6-Tg (Marfia)

Shah clinical protocols:

  • A Multicenter, Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of AMG 145 on LDL-C in Subjects with Severe Familial Hypercholesterolemia (TAUSSIG: Trial Assessing long-term USe of PCSK9 Inhibition in Subject with Genetic LDL Disorders; Protocol 20110271)
  • A Double-blind, Randomized, Multicenter Study to Evaluate the Safety and Efficacy of AMG 145, Compared With Ezetimibe, in Hypercholesterolemic Subjects Unable to Tolerate an Effective Dose of a HMG-CoA Reductase Inhibitor Due to Muscle Related Side Effects (Protocol 20120332;GAUSS-3)
  • Open-Label Extension Study of EFC12492, R727-CL1112, EFC12732 & LTS11717 Studies to Assess the Long-Term Safety and Efficacy of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia
  • LOWER: Lomitapide Observational Worldwide Evaluation Registry
  • A Multicenter, Controlled, Open-Label Extension (OLE) Study to Assess the Long-term Safety and Efficacy of AMG 145 (Protocol 20120138; OSLER-2 Open Label Study of Long-Term Evaluation Against LDL-C Trial)

Kuang-Yuh Chyu, MD, PhD, and Paul Dimayuga, PhD, resources for current animal studies developed for atherosclerosis research:

  • Role of Cathelin-Related Anti-Microbial Peptide (CRAMP)-specific CD8+ T cells in atherosclerosis
  • Role of CD8+ regulatory T cells in atherosclerosis
  • Comparison of 15 ApoB-100 peptide based vaccines
  • Role of DC in ApoB-100 peptide vaccine
  • Effect of p210 based immunization on AAA and hypertension 
  • Effect of lipid lowering on immune function in ApoE (-/-) mice
  • Screening for efficacy of different formulations of p210 vaccine
  • Role of CD8+ T regulatory cells in the protective effect of a peptide vaccine against atherosclerosis
  • Effect of immunization with an ApoB-100 peptide, p210, on Kawasaki disease (KD) vasculitis
  • Efficacy of immunization with p210-based vaccines in modulating transplant vasculopathy
  • Characterization of p210 specific CD8+ T cells in murine and human atherosclerosis
  • Development of accelerated atherosclerosis in an SLE model in ApoE (-/-) mice
  • Characterization of immune responses to p210 vaccines in murine model of atherosclerosis 
  • Atherosclerotic mouse model transgenic for Class-I HLA0201
  • Discovery and screening of peptide self-antigens in coronary artery disease
Contact the Shah Lab

127 S. San Vicente Blvd.
Advanced Health Sciences Pavilion, 9th Floor
Los Angeles, CA 90048